Galantamine hydrobromide

[7,8-³H]Dopamine (21.2 Ci/mmol (0.784 TBq/mmol)) and [1-7,8-³H]noradrenaline (12.1 Ci/mmol (0.448 TBq/mmol)) were purchased from Perkin Elmer, Monza, Italy. Nicotine hydrogen tartrate salt, choline, 4-aminopyridine, 6-nitroquipazine, desipramine, beta-amyloid (40-1), horseradish peroxidase-conjugated anti-mouse secondary antibody, Ponceau Red were from Sigma (Sigma-Aldrich, St Louis, MO, USA); Monoclonal antibody 6E10 was from Covance ImmunoTechnologies, Dedham, MA; 5-iodo-A-85380, dihydro-β-erythroidine, α-conotoxin MII, oxotremorine sesquifumarate, desformylflustrabromine hydrochloride, galantamine hydrobromide, SR 165845, beta-amyloid (1-40) were from Tocris (Tocris Bioscience, Bristol, UK).

(−)Nicotine hydrogen tartrate salt (Sigma Aldrich, St. Louis, MO, USA) was dissolved in sterile 0.9% saline (pH was adjusted to 7.4±0.5 with sodium hydroxide). Galantamine hydrobromide and donepezil hydrochloride (Tocris, Ellisville, MS, USA) were dissolved in sterile 0.9% saline. Nicotine doses are reported as freebase concentrations whereas galantamine and donepezil concentrations are reported as their salt concentrations. Investigational Drug Services at the University of Pennsylvania packaged Galantamine hydrobromide extended release and placebo in matching capsules to ensure double-blind testing conditions. The dosing regimen consisted of an initial 1-week 8 mg galantamine run-up (daily). During week 2, the dose was titrated to the recommended 16 mg daily dose.^{37 (link)} Participants were instructed to take the study medication at the same time each day, preferably in the morning and with food. Medication adherence was assessed by participant self-report and confirmed with reconciliation of medication dispensed versus returned. Adherence was calculated as percentage of pills consumed (out of 14).